Peptide Research Databases: A Verification Workflow

No single database answers identity, mechanism, human efficacy, approval, and product quality. A PubMed citation may describe a related analog rather than the peptide on a label. A ClinicalTrials.gov record may describe a study that never reported results. A chemical identifier may resolve the molecule but say nothing about whether it works. A certificate of analysis may describe one batch but cannot establish clinical benefit.

The useful skill is therefore not memorizing a list of websites. It is matching each claim to the database capable of testing it, then recording exactly what the source does and does not establish.

Short answer

For a defensible peptide search:

1. Resolve identity first. Record the exact name, aliases, sequence or chemical form, organism, analog, salt, conjugate, and accession identifiers.
2. Search literature broadly. Use PubMed for publications, but inspect the original methods rather than treating an abstract or publication type as a verdict.
3. Check human-study registration separately. ClinicalTrials.gov can show study design, status, outcomes, and posted results. A registered study is not an approved treatment.
4. Separate structure from effect. UniProt, PubChem, RCSB PDB, AlphaFold DB, and ChEMBL answer different molecular questions. A structure is not clinical evidence.
5. Verify regulatory status in regulator-owned sources. In the United States, use Drugs@FDA and the Purple Book rather than a retailer, search snippet, or general drug directory.
6. Match the studied material to the offered product. Evidence for a native peptide, analog, approved formulation, or full-length protein does not automatically transfer to a fragment, different salt, compounded preparation, or research vial.
7. Keep quality evidence separate. Identity, amount, purity, sterility, endotoxin, and stability require batch- and product-specific records. None proves efficacy.

This workflow supports the wiki's research methodology, sourcing policy, and source availability and batch-record directory.

Match the question to the source

Step 1: resolve the exact peptide identity

Name ambiguity is the most common reason a search looks stronger than it is. Before evaluating a claim, make a small identity record:

This matters for common peptide searches. Humanin and the engineered analog HNG are related but not identical. Full-length thymosin beta-4 is not interchangeable with the short material sold as TB-500. Epitalon and the tissue extract historically called Epithalamin are different materials. An alias map prevents evidence from one object being silently assigned to another.

UniProt is especially useful for endogenous peptides, but read the feature annotations. Its canonical sequence can represent a precursor that is processed into signal peptides, propeptides, chains, or mature peptides. Prefer reviewed entries when available, and still follow the cited experimental evidence. PubChem is useful for chemical cross-references, but a matching name or depositor record should be reconciled with sequence, stereochemistry, and the original source.

Step 2: search PubMed without filtering away the answer

Start with the exact name and aliases, then add one concept at a time. For example:

"peptide-name" OR "alternate name" OR "sponsor code"
("peptide-name" OR "alternate name") AND condition
("peptide-name" OR "alternate name") AND (trial OR randomized OR pharmacokinetics)

Then inspect each candidate paper for the exact intervention, species, model, route, comparator, sample size, outcomes, and conflicts. The how to read peptide research guide provides a fuller appraisal workflow.

Use PubMed filters after checking the broad landscape. The PubMed User Guide notes that article-type and species filters rely partly on publication-type or MeSH indexing. New, ahead-of-print, preprint, and some non-MEDLINE records may not yet carry those fields. An early Humans or Clinical Trial filter can therefore remove relevant records rather than merely improving precision.

Also check the record for corrections, expressions of concern, retractions, linked data, and related articles. A review can map a field, but it should not replace the original study when a claim depends on its exact methods or result.

Google Scholar can help discover theses, citations, or records outside PubMed. Treat it as discovery, not verification: open the original source, identify its publication status, and record a stable DOI, PMID, registry ID, or repository record where possible.

Step 3: read the trial record, not just the status badge

Search ClinicalTrials.gov using all aliases and sponsor codes. For each plausible record, capture:

• NCT number and last update date
• study type: interventional, observational, or expanded access
• actual intervention: the administered product, comparator, dose form, and route
• phase and allocation, when applicable
• recruitment status and why a study was stopped, if reported
• primary outcome measures, time frames, and enrollment
• primary completion and study completion dates
• posted results, adverse-event tables, and linked publications
• sponsor and responsible party

Completed does not mean successful. It normally means the study ended according to its record; it says nothing by itself about whether the primary outcome was met, whether results were posted, or whether regulators found the product safe and effective. Likewise, Recruiting means the protocol is seeking participants, not that the intervention works.

Compare posted registry outcomes with the publication. Look for changed outcomes, different analysis populations, missing adverse-event data, or a publication that describes a related but not identical intervention. The registry's How to Read a Study Record and Data API are the authoritative starting points for field definitions and structured retrieval.

Step 4: interpret structure and pharmacology in context

Experimental and predicted structures

RCSB PDB stores experimentally derived macromolecular structure data and validation information. Confirm the construct, sequence positions, mutations, ligand, binding partner, experimental method, and unresolved regions. A receptor complex can clarify a binding pose without showing that a product improves a health outcome.

AlphaFold DB provides computed structure models. Inspect confidence across the region of interest and remember that a confident local fold does not prove a dynamic conformation, receptor interaction, formulation behavior, or clinical effect. Do not present an AlphaFold model as if it were a deposited experimental structure.

Bioactivity databases

ChEMBL links molecules, targets, assays, and primary literature. Before comparing two numbers, verify:

• the exact molecule and target construct
• species and cell or biochemical system
• endpoint type and units
• whether the result is an exact value, range, or qualifier
• assay conditions and source paper
• whether the record measures binding, functional response, exposure, or toxicity

IC50, EC50, Kd, and Ki are not interchangeable. They describe different experimental quantities, and even two values with the same label may not be comparable across assay systems. None is a human dose recommendation. Use the ChEMBL training guide to understand the record structure, then verify the primary paper.

Step 5: verify approval and labeling separately

For U.S. drug claims, search the exact active ingredient and brand in Drugs@FDA. Record the application number, dosage form, route, approval history, and current FDA-approved indication. For biological products licensed under the Public Health Service Act, check the Purple Book.

Use DailyMed to inspect current labeling submitted to FDA and in use. Do not use a DailyMed result alone as an approval test: the collection also contains labeling for nonprescription products, animal drugs, devices, cosmetics, dietary supplements, medical foods, and other categories. FDA notes that company-submitted current labeling can also differ from the last FDA-approved labeling in Drugs@FDA.

Three distinctions prevent most regulatory errors:

1. An approved ingredient is not every product with that name. Approval attaches to a specific application, manufacturer, dosage form, route, strength, indication, and labeling.
2. An approved use is not every proposed use. Off-label literature, trial registration, and marketing claims do not expand the approved indication.
3. Compounding is not FDA approval. FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing.

For European claims, use the European Medicines Agency medicine search and the relevant national regulator. A U.S. approval, EU authorization, national authorization, and trial registration are different statuses.

Step 6: audit a product or seller claim

Break a broad claim into separately verifiable parts:

When a source answers only one layer, do not let it stand in for the others. A molecular model cannot validate a batch. A COA cannot turn animal evidence into human evidence. A registered study cannot establish approval. A seller's use of the words “pharmaceutical grade,” “clinical grade,” or “research use only” does not resolve any of those questions by itself.

Use the purity-testing guide to interpret analytical records and the manufacturing guide to separate synthesis, purification, release testing, and finished-product quality.

A repeatable eight-step research note

1. State the claim exactly. Avoid broad prompts such as “Does it work?”
2. Create the identity map. Record names, sequence/form, organism, analog relationship, and identifiers.
3. Map the literature. Search aliases broadly, then classify cell, animal, observational human, interventional human, and review evidence.
4. Check trial registries. Capture status, intervention, outcomes, dates, results, and sponsor rather than only counting records.
5. Appraise the primary evidence. Confirm methods, comparator, sample size, effect size, uncertainty, adverse events, and conflicts.
6. Verify regulatory status. Use regulator-owned records and match the exact product, route, indication, and jurisdiction.
7. Compare product with evidence. Document any difference in molecule, formulation, route, concentration, source, or lot.
8. Record limits and a review date. State what remains unknown and when time-sensitive searches were last repeated.

That note can feed a profile in the peptide library or a question-led comparison in the use-case directory without blurring discovery, evidence, regulation, and commerce.

References and official database guidance

• National Library of Medicine. PubMed User Guide.
• ClinicalTrials.gov. How to Read a Study Record and Data API.
• UniProt Consortium. Sequence processing, sequence annotation, and reviewed/unreviewed filters.
• RCSB Protein Data Bank. About RCSB PDB.
• EMBL-EBI and Google DeepMind. AlphaFold Protein Structure Database FAQ.
• EMBL-EBI. ChEMBL and What is ChEMBL?.
• National Center for Biotechnology Information. PubChem.
• U.S. Food and Drug Administration. Approved Drugs: Questions and Answers and Resources for Information on Approved Drugs.
• U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
• National Library of Medicine. DailyMed.